How to Evaluate Patients and Educate Them About Self-Examinations for Tardive Dyskinesia Between Appointments

In brief videos, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.

Abstract

Patients taking dopamine-blocking agents such as antipsychotics are at risk for developing tardive dyskinesia. In this webcast, Drs McEvoy and Nierenberg discuss symptoms of tardive dyskinesia (TD), how to observe patients (whether in person or via telemedicine), and how to educate patients and families about TD.

From the Series: Diagnosing, Treating, and Educating Patients With Tardive Dyskinesia

To cite: McEvoy JP, Nierenberg AA. How to Evaluate Patients and Educate Them About Self-Examinations for Tardive Dyskinesia Between Appointments. J Clin Psychiatry. 2021;82(1):NU19047WC6C.

To share: https://doi.org/10.4088/JCP.NU19047WC6C

© Copyright 2021 Physicians Postgraduate Press, Inc.

Target Audience

  • Psychiatrists
  • Neurologists
  • Nurse practitioners and physician assistants who specialize in neurology and/or psychiatry
  • Primary care clinicians

Learning Objectives

  • Conduct regular screening for signs of tardive dyskinesia (TD)
  • Provide patient/family education about symptoms of tardive dyskinesia (TD) and self-evaluation between appointments
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
01/19/2021
Activity expires: 
01/31/2023
Cost:
$0.00
Rating: 
0

Support Statement

Supported by an educational grant from Neurocrine Biosciences, Inc.

Learning Objective

After completing this educational activity, you should be able to:

  • Conduct regular screening for signs of tardive dyskinesia (TD)
  • Provide patient/family education about symptoms of tardive dyskinesia (TD) and self-evaluation between appointments

Release, Review, and Expiration Dates

This brief report activity was published in January 2021 and is eligible for AMA PRA Category 1 Credit™ through January 31, 2023. The latest review of this material was October 2020.

Statement of Need and Purpose

Clinicians may not recognize early TD symptoms, as mild cases may be more easily missed. A substantial proportion of patients with TD do not have a timely diagnosis, meaning that treatment is delayed and the chance for a poor outcome is increased. Because some clinicians underestimate the risk of TD, especially with newer antipsychotics, they do not advise patients and caregivers of the risk of TD or educate them about early signs to watch for and report. Therefore, clinicians need education on the rates of TD with SGAs and FGAs; risk factors for the development of TD; how to use assessment tools that will help them diagnose and monitor TD; and discussing TD risk and signs with patients and caregivers. In addition, physicians need awareness of evidence-based, expert guidance on using approved medications in the treatment of TD, because effective medications for TD are available, and evidence-based treatment recommendations have been published.

Disclosure of Off-Label Usage

Dr McEvoy has determined that, to the best of his knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.

Review Process

The faculty members agreed to provide a balanced and evidence-based presentation and discussed the topics and CME objectives during the planning sessions. The faculty’s submitted content was validated by CME Institute staff, and the activity was evaluated for accuracy, use of evidence, and fair balance by the Chair and a peer reviewer who is without conflict of interest.

Acknowledgment

This activity is derived from the teleconference series “JCP Fundamentals: Getting Back to the Basics—Diagnosing, Treating, and Educating Patients With Tardive Dyskinesia,” which was held in March–September 2020 and supported by an educational grant from Neurocrine Biosciences, Inc. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher or the commercial supporter.

Faculty Affiliation

Joseph P. McEvoy, MD
Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University

 

Andrew A. Nierenberg, MD
Dauten Family Center for Bipolar Treatment Innovation and the Depression Clinical and Research Program, Massachusetts General Hospital, and Department of Psychiatry, Harvard Medical School, Boston


Financial Disclosure

The faculty for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal and financial relationships between themselves or their spouse/partner and any commercial interest. The Accreditation Council for Continuing Medical Education (ACCME) defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Faculty financial disclosures are as follows:

The Chair for this activity, Joseph P. McEvoy, MD, has received grant/research support from Biogen, Alkermes, Boehringer Ingelheim, Takeda, Auspex (Teva), and Lundbeck and is a member of the speaker/advisory boards for Intracellular and Sunovion. Andrew A. Nierenberg, MD, is a consultant for Acadia, Eisai, and Myriad Genetics and is a member of the speaker/advisory boards for Alkermes, Jazz, Safe, Otsuka, and Neuronetics.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this activity.

Register for free on our site to participate in this and many other free CME courses.